Himalayas-1 randomizes 1:1 to rinzimetostat 400 mg daily plus darolutamide vs physician’s choice ARPI or docetaxel in mCRPC progressing after abiraterone. Radiographic PFS is the primary end point, ...

A secondary analysis of the ASPIRE trial found residual stone volume—not conventional stone-free status, baseline volume, or density—is the strongest predictor of post-ureteroscopy health care ...

This digital series features articles and videos with insights and expert viewpoints on PSMA-PET and the evolving imaging paradigm that is revolutionizing the diagnosis and treatment of patients with ...

Many factors play into decision-making process when weighing agents. In the 1940s, Huggins and Hodges’ Nobel prize–winning work firmly established the therapeutic effect of testosterone deprivation in ...

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...

"We knew that the MS or momentary squeeze pump, originally designed at AMS was a fine device, but it did have some issues. We thought we could make it even better," says Ronald A. Morton, MD. The ...

A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...

Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...

VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...

"Because it takes advantage of a viral vector and is delivered as a gene therapy product, what it can do is it can have sustained release of IFNα2b in the bladder," says Vikram M. Narayan, MD. In this ...

“The key finding is [that] this might be, in itself, a novel risk factor for bladder cancer," says Laura E. Davis, MD. Data presented at the 2025 American Urological Association (AUA) Annual Meeting ...

FDA Breakthrough Device Designation was granted to an AI-powered H&E-based prognostic assay for bladder cancer, described as the first such designation in this disease setting. Proprietary foundation ...